1. Intravenous antiplatelet therapy with cangrelor vs. tirofiban in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. (3rd October 2022) Authors: Centore, M; Silverio, A; Scudiero, F; Di Maio, M; Muraca, I; Dossi, F; Petrini, F; Brenca, D; Maiellaro, F; Attisano, T; Parodi, G; Musumeci, G; Galasso, G Journal: European heart journal Issue: Volume 43(2022)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. M-health and telemedicine: are people ready for the future? A real-world survey. (25th November 2020) Authors: Dossi, F; Marini, A; Sanna, G.D; Saba, P.S; Parodi, G Journal: European heart journal Issue: Volume 41:(2020)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Orodispersible ticagrelor use in acute coronary syndrome patients: the Ticagrelor Administered as Standard Tablet or orodispersiblE foRmulation (TASTER) Study. (25th November 2020) Authors: Parodi, G; Talanas, G; Mura, E; Corda, G; Dossi, F; Canonico, M.E; Guarino, S; Nusdeo, G; Franca, P; Raccis, M; Pisano, M; Sanna, G.D; Saba, P.S Journal: European heart journal Issue: Volume 41:(2020)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗